Tuesday 16 July 2019 ,
Tuesday 16 July 2019 ,
Latest News
  • 9 killed as train hits microbus in Sirajganj
  • No more unplanned construction, industrialisation: PM
  • Plan underway to air all good classes thru’ TV channel: Dipu Moni
  • PM stresses waterway connectivity with India to promote trade
  • No gas, power connection to industries set up in undesignated areas: Nasrul
  • Nusrat murder: HC orders probe against addl magistrate
16 April, 2019 00:00 00 AM

Recurrence score may cut costs for high-risk breast cancer care

drugs.com
Recurrence score may cut costs for high-risk breast cancer care

Genomic recurrence score (RS) testing using a 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients with breast cancer who would otherwise receive standard chemotherapy, according to a study published in the March issue of the Journal of the National Comprehensive Cancer Network.

Michaela A. Dinan, Ph.D., from the Duke University School of Medicine in Durham, North Carolina, and colleagues used SEER-Medicare data to identify a nationally representative sample of 30,058 Medicare beneficiaries diagnosed with early-stage, estrogen receptor-positive breast cancer from 2005 through 2011. Associations between RS testing and overall and chemotherapy-specific costs were evaluated.

The researchers found that 17.5 percent of patients received RS testing; of these, 13.3 percent were initially clinically classified as low-risk, 69.5 percent as intermediate-risk, and 17.2 percent as high-risk. One year after diagnosis, mean costs were $35,940 overall, $51,127 for clinically high-risk disease, $33,225 for intermediate-risk disease, and $26,695 for low-risk disease. Similar trends were seen for chemotherapy-specific costs.

RS testing was associated with significantly lower costs among high-risk patients for both relative costs (cost ratio, 0.88) and absolute costs ($6,606). In low-risk and intermediate-risk patients, higher costs were mainly caused by higher noncancer costs. In analyses of all 64,996 patients aged ≥66 years, associations between RS testing and costs among high-risk patients were similar but less marked because of lower overall use of chemotherapy.

"In the big picture, the ability for RS testing to reduce either the cost of chemotherapy or total health costs may depend on the general distribution of patients who are clinically considered to be high-, intermediate-, or low-risk," Dinan said in a statement.

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

Reproductive life starts at puberty with onset of adult sexual life. Reproductive health is vital issue throughout the world as it concerned with population…
Sexual and reproductive health

Sexual and reproductive health

Good sexual and reproductive health is a state of complete physical, mental and social well-being in all matters relating to the reproductive system.…
Sexual health issues

Sexual health issues

Sexual health is a broad area that encompasses many inter-related challenges and problems. Key among the issues and concerns are human rights related…
Infertility & reproduction health

Infertility & reproduction health

Some fertility problems are more easily treated than others. In general, as a woman ages, especially after age 35, her chances of getting pregnant go…
Reproductive health and 
environmental exposure

Reproductive health and environmental exposure

The influence of the environment on human reproduction is a concern in all countries and anxiety has been increased following disasters such as those…

Understanding Premenstrual Syndrome

Premenstrual syndrome (PMS) is a condition that affects a woman’s emotions, physical health, and behavior during certain days of the menstrual cycle, generally just before her menses. PMS is a very common condition. Its symptoms affect more than 90 percent of menstruating women. It must impair…
The bamboo spine- Ankylosing spondylitis

The bamboo spine- Ankylosing spondylitis

Ankylosing Spondylitis means inflammation of the spine causing pain and stiffness of the back. When ankylosing spondylitis is not treated, it leads to…
Finger-prick blood test could help reduce antibiotic use for some patients

Finger-prick blood test could help reduce antibiotic use for some patients

A simple finger-prick blood test could help prevent unnecessary prescribing of antibiotics for people with the lung condition chronic obstructive pulmonary…
14 Natural remedies to beat insomnia

14 Natural remedies to beat insomnia

CATHY WONG Although it's common to have the occasional sleepless night, insomnia is the inability to sleep or excessive wakening in the night that…
Vaginal bacteria linked to ovarian cancer

Vaginal bacteria linked to ovarian cancer

Having too few "friendly" vaginal bacteria may increase a woman's chance of ovarian cancer, and swabs can be used to spot this, say researchers.…
For kids with rare condition, 'Restricted' diets can turn dangerous

For kids with rare condition, 'Restricted' diets can turn dangerous

Two young patients -- one 3 and the other 13 -- have a rare condition that calls for a highly restricted diet. Both have so much trouble eating that they…
Hospitalized pneumonia patients often get excess antibiotics

Hospitalized pneumonia patients often get excess antibiotics

Patients hospitalized with pneumonia often receive excess antibiotic therapy, according to a study published online July 9 in the Annals of Internal Medicine.…
Flu vaccine safe during pregnancy

Flu vaccine safe during pregnancy

Pregnant women can take comfort in new findings that suggest flu vaccines won't harm their fetuses. Canadian researchers examined data on more than…

Vyleesi bremelanotide for hypoactive sexual desire disorder

Vyleesi is a prescription medicine used to treat hypoactive (low) sexual desire disorder (HSDD) in women who have not gone through menopause, who have not had problems with low sexual desire in the past, and who have low sexual desire no matter the type of sexual activity, the situation, or the sexual…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting